$1.69
-0.005[-0.29%]
At close: Apr 22
$1.69
0[0.00%]
After Hours: 4:01PM EDT
Sonnet BioTherapeutics
(NASDAQ:SONN)Sonnet BioTherapeutics Stock (NASDAQ:SONN), Analyst Ratings, Price Targets, Predictions
Sonnet BioTherapeutics Holdings Inc has a consensus price target of $8.78, established from looking at the 17 latest analyst ratings. The last 3 analyst ratings were released from Chardan Capital, Ladenburg Thalmann, and EF Hutton on February 15, 2024, November 27, 2023, and August 23, 2023. With an average price target of $14.57 between Chardan Capital, Ladenburg Thalmann, and EF Hutton, there's an implied 761.93% upside for Sonnet BioTherapeutics Holdings Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Chardan Capital
Ladenburg Thalmann
EF Hutton
BTIG
HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Sonnet BioTherapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/15/2024 | SONN | Buy Now | Sonnet BioTherapeutics | $1.69 | 1675.15% | Chardan Capital | Keay Nakae | $75 → $30 | Maintains | Buy | Get Alert |
| 11/27/2023 | SONN | Buy Now | Sonnet BioTherapeutics | $1.69 | 314.2% | Ladenburg Thalmann | Ahu Demir | → $7 | Initiates | → Buy | Get Alert |
| 08/23/2023 | SONN | Buy Now | Sonnet BioTherapeutics | $1.69 | 296.45% | EF Hutton | Michael King | → $147.4 | Assumes | → Buy | Get Alert |
| 08/16/2023 | SONN | Buy Now | Sonnet BioTherapeutics | $1.69 | 610.06% | Chardan Capital | Keay Nakae | $308 → $264 | Maintains | Buy | Get Alert |
| 06/26/2023 | SONN | Buy Now | Sonnet BioTherapeutics | $1.69 | 296.45% | EF Hutton | Michael King | → $147.4 | Reiterates | Buy → Buy | Get Alert |
| 05/25/2023 | SONN | Buy Now | Sonnet BioTherapeutics | $1.69 | 296.45% | EF Hutton | Michael King | → $147.4 | Assumes | → Buy | Get Alert |
| 05/11/2023 | SONN | Buy Now | Sonnet BioTherapeutics | $1.69 | 728.4% | Chardan Capital | Keay Nakae | $374 → $308 | Maintains | Buy | Get Alert |
| 04/19/2023 | SONN | Buy Now | Sonnet BioTherapeutics | $1.69 | 296.45% | EF Hutton | Michael King | → $147.4 | Reiterates | → Buy | Get Alert |
| 04/19/2023 | SONN | Buy Now | Sonnet BioTherapeutics | $1.69 | 905.92% | Chardan Capital | Keay Nakae | $484 → $374 | Maintains | Buy | Get Alert |
| 02/15/2023 | SONN | Buy Now | Sonnet BioTherapeutics | $1.69 | 296.45% | EF Hutton | Michael King | → $147.4 | Reiterates | → Buy | Get Alert |
| 12/19/2022 | SONN | Buy Now | Sonnet BioTherapeutics | $1.69 | 296.45% | EF Hutton | Michael King | → $147.4 | Initiates | → Buy | Get Alert |
| 09/22/2022 | SONN | Buy Now | Sonnet BioTherapeutics | $1.69 | 1201.78% | Chardan Capital | Keay Nakae | $44 → $484 | Maintains | Buy | Get Alert |
| 08/16/2022 | SONN | Buy Now | Sonnet BioTherapeutics | $1.69 | 18.34% | Chardan Capital | Keay Nakae | $770 → $616 | Maintains | Buy | Get Alert |
| 02/09/2022 | SONN | Buy Now | Sonnet BioTherapeutics | $1.69 | 18.34% | BTIG | Kaveri Pohlman | $1540 → $616 | Maintains | Buy | Get Alert |
| 12/20/2021 | SONN | Buy Now | Sonnet BioTherapeutics | $1.69 | 47.93% | Chardan Capital | Keay Nakae | — | Maintains | Buy | Get Alert |
| 12/16/2021 | SONN | Buy Now | Sonnet BioTherapeutics | $1.69 | 18.34% | HC Wainwright & Co. | Michael King | — | Initiates | → Buy | Get Alert |
| 09/15/2021 | SONN | Buy Now | Sonnet BioTherapeutics | $1.69 | 195.86% | BTIG | — | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Sonnet BioTherapeutics (SONN)?
The latest price target for Sonnet BioTherapeutics (NASDAQ: SONN) was reported by Chardan Capital on February 15, 2024. The analyst firm set a price target for $30.00 expecting SONN to rise to within 12 months (a possible 1675.15% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sonnet BioTherapeutics (SONN)?
The latest analyst rating for Sonnet BioTherapeutics (NASDAQ: SONN) was provided by Chardan Capital, and Sonnet BioTherapeutics maintained their buy rating.
When was the last upgrade for Sonnet BioTherapeutics (SONN)?
There is no last upgrade for Sonnet BioTherapeutics.
When was the last downgrade for Sonnet BioTherapeutics (SONN)?
There is no last downgrade for Sonnet BioTherapeutics.
When is the next analyst rating going to be posted or updated for Sonnet BioTherapeutics (SONN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sonnet BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sonnet BioTherapeutics was filed on February 15, 2024 so you should expect the next rating to be made available sometime around February 15, 2025.
Is the Analyst Rating Sonnet BioTherapeutics (SONN) correct?
While ratings are subjective and will change, the latest Sonnet BioTherapeutics (SONN) rating was a maintained with a price target of $75.00 to $30.00. The current price Sonnet BioTherapeutics (SONN) is trading at is $1.69, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.